Using fecal microbiota transplantation and fiber to treat graft-versus-host disease after blood cell transplants
Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation
This study is looking at how using a special treatment called fecal microbiota transplantation, along with dietary fiber, can help improve gut health and recovery for patients dealing with graft-versus-host disease after a stem cell transplant.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10908690 on NIH RePORTER |
What this research studies
This research investigates the use of fecal microbiota transplantation (FMT) combined with dietary fiber to treat graft-versus-host disease (GvHD) in patients who have undergone allogeneic hematopoietic cell transplantation. GvHD is a serious complication that affects many transplant recipients, leading to significant health issues. The study aims to explore how different methods of delivering FMT can help restore gut bacteria and improve patient outcomes. By understanding the role of gut microbiota in GvHD, the research seeks to identify effective treatment strategies that could enhance recovery and quality of life for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone allogeneic hematopoietic cell transplantation and are experiencing symptoms of graft-versus-host disease.
Not a fit: Patients who have not undergone hematopoietic cell transplantation or those without graft-versus-host disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves recovery and quality of life for patients suffering from graft-versus-host disease.
How similar studies have performed: Previous studies have shown promising results with fecal microbiota transplantation in similar contexts, indicating potential for success in this novel application.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Fredricks, David Neal — Fred Hutchinson Cancer Center
- Study coordinator: Fredricks, David Neal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.